Davis Gregory D 4

What Happened Gregory D. Davis, Head of Research & Technology at Sangamo Therapeutics (SGMO), had a portion of his RSU award vest on May 25, 2026 and surrendered 1,630 shares to the company to satisfy mandatory tax withholding. The filing reports the disposition at $0.17/share for a total of $284; the issuer's closing price used for withholding was $0.1743/share.

Key Details

• Transaction date: May 25, 2026; Form 4 filed May 27, 2026 (appears timely).
• Disposition: 1,630 shares surrendered for tax withholding; reported price $0.17/share (issuer closing price used for withholding: $0.1743/share); total ~$284.
• Vesting detail: 3,031 shares vested on May 25, 2026; 1,630 of those were surrendered for taxes, leaving 1,401 vested shares delivered to the reporting person from this installment.
• Future vesting: An additional 32,633 shares from the February 25, 2025 RSU grant remain and will vest in seven equal quarterly installments, subject to continued service and plan terms (per footnote).
• Footnote nature: This was a mandatory tax-withholding disposition (code F) and not an open-market sale or discretionary trade.

Context This was a routine tax-withholding transaction tied to RSU vesting, not a market sale intended to realize gains. Such withholding dispositions are common when equity awards vest and generally do not signal insider sentiment about the company's prospects.